Cite
HARVARD Citation
Rehman, M. et al. (2021). Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC. JCO precision oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Rehman, M. et al. (2021). Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC. JCO precision oncology. p. . [Online].